Skip to content
Checking whether you are signed in

Intuitive Surgical, Inc.

ISRGNasdaqFull coverage

Price
Loading your watchlists

AI-generatedPublished Nov 1, 2026, 8:18 PM UTC

Q3 fiscal 2026 edition

A free account unlocks one dossier edition a month.

Create a free account

Already have an account? Sign in

Summary

Free to read

Intuitive Surgical makes the da Vinci surgical robot and earns most of its revenue afterwards, from the instruments used in every operation and from service contracts, which made up 84% of revenue in the third quarter of 2026. Revenue grew 21.7% to $3.05 billion in the quarter, but worldwide da Vinci procedure growth slowed for the fourth quarter running, to about 14%, with the US at about 10%. The company plans to cut instrument revenue per procedure by about 3% to 5% from 2027 to widen adoption in cost-sensitive benign surgery, while new robots from Medtronic, Johnson & Johnson and Stryker reach the US market. Moatsight estimates revenue of about $13.1 billion over the next four quarters, with growth slowing through 2027.

In the full dossier

  1. Part 1In brief
  2. Part 2Business explainer
  3. Part 3Earnings
  4. Part 4Valuation and projections
  5. Part 5What changed

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers